



TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
3405/US

Re Application Of: Michael J. Hageman et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/730,663	December 6, 2000	Golam M. Shameem	26648	1626	8091

Title: **SOLID STATE FORM OF CELECOXIB EXHIBITING ENHANCED BIOAVAILABILITY**
solid state form of celecoxib
exhibiting enhanced bioavailability

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Amendment Transmittal; Response to Office Action; Itemized Postcard.

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1025** as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Patricia K. Fitzsimmons
Signature

Dated: March 14, 2005

Patricia K. Fitzsimmons, Reg. No. 52,894
Pharmacia Corporation of Pfizer Inc.
P.O. Box 1027
Chesterfield, Missouri 63006
314.274.1490

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
March 14, 2005

(Date)
Linda K. Cooper
Signature of Person Mailing Correspondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence

CC:

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Applicant(s): Michael J. Hageman et al.

Docket No.

3404/US

Application No.

09/730,663

Filing Date

December 6, 2000

Examiner

Golam M. Shameem

Customer No.

26648

Group Art Unit

1626

Confirmation No.

8091

Invention:

SOLID STATE FORM OF CELECOXIB EXHIBITING ENHANCED BIOAVAILABILITY

COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	4 -	35 =	0	x \$50.00	\$0.00
INDEP. CLAIMS	2 -	17 =	0	x \$200.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00

☒ No additional fee is required for amendment.

☐ Please charge Deposit Account No. _____ in the amount of _____

☐ A check in the amount of _____ to cover the filing fee is enclosed.

☒ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1025

☒ Any additional filing fees required under 37 C.F.R. 1.16.

☐ Any patent application processing fees under 37 CFR 1.17.

☐ Payment by credit card. Form PTO-2038.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Patricia K. Fitzsimmons
Signature

Dated: March 14, 2005

Patricia K. Fitzsimmons, Reg. No. 52,894
Pharmacia Corporation of Pfizer Inc.
P.O. Box 1027
Chesterfield, Missouri 63006
314.274.1490

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

March 14, 2005

(Date)

Linda K. Cooper
Signature of Person Mailing Correspondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence

CC:



800
1626

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Hageman et al.) GROUP ART UNIT: 1626
SERIAL NO.: 09/730,663) CONFIRMATION NO.: 8091
EXAMINER: Shameem) ATTORNEY DOCKET NO.: S03405/US
FILED: December 6, 2000)
TITLE: SOLID STATE FORM OF CELECOXIB EXHIBITING ENHANCED BIOAVAILABILITY

CERTIFICATE OF MAILING

I hereby certify that this communication and any recited enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on **March 14, 2005**.


Linda K. Cooper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

March 14, 2005
(The first business day after Sunday, March 13, 2005)

RESPONSE TO OFFICE ACTION

Sir:

In response to the Office action of December 13, 2004, please consider the following remarks.